Get started
Author

Neeta D. Pandit-Taskar

Observed names: N Pandit-Taskar, N. Pandit-Taskar, N. Pandit-taskar, N. Pandit‐Taskar, Neeta Pandit-Taskar, Neeta Pandit‐Taskar, Pandit-Taskar, Neeta
Observed institutions: Fox Chase Cancer Center, Tufts Medical Center, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Children's Hospital of Philadelphia, University of Padua, Johns Hopkins University, University of Pittsburgh, Washington University in St. Louis, Cornell University, Society of Nuclear Medicine and Molecular Imaging, Rigshospitalet, Massachusetts General Hospital, Parker Institute for Cancer Immunotherapy, Shriners Hospitals for Children - Boston, Joint Research Centre, University of Pittsburgh Medical Center, Actinium Pharmaceuticals (United States), Ludwig Cancer Research, Memorial Hospital, Weill Cornell Medicine, Weill Cornell Medical Center, New York University, University of Pennsylvania, Stanford University
ORCID: 0000-0003-1551-2036
Observed ORCID: 0000-0003-1551-2036
OpenAlex ID: A5010076893
European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma
2019 · David Taïeb, Rodney J. Hicks, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 405
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial
2007 · Chaitanya R Divgi, Neeta Pandit-Taskar, et al. · The Lancet Oncology · 388
Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia
2010 · Todd L. Rosenblat, Michael R. McDevitt, et al. · Clinical Cancer Research · 272
PDF
Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial
2018 · Mark M Souweidane, Kim Kramer, et al. · The Lancet Oncology · 267
First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
2019 · Neeta Pandit-Taskar, Michael A. Postow, et al. · Journal of Nuclear Medicine · 257
PDF
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
2009 · Kim Kramer, Brian H. Kushner, et al. · Journal of Neuro-Oncology · 247
Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.
2004 · Neeta Pandit-Taskar, Maria Batraki, et al. · PubMed · 224
Sentinel lymph node mapping for grade 1 endometrial cancer: Is it the answer to the surgical staging dilemma?
2009 · Nadeem R. Abu-Rustum, Fady Khoury-Collado, et al. · Gynecologic Oncology · 218
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
2015 · Neeta Pandit-Taskar, Joseph A. O'Donoghue, et al. · Clinical Cancer Research · 195
Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer
2013 · Jorge A. Carrasquillo, Joseph A. O’Donoghue, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 185
Radiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates
2016 · Brian Quinn, Zak Dauer, et al. · BMC Medical Imaging · 177
PDF
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial
2024 · Brian Shuch, Allan J Pantuck, et al. · The Lancet Oncology · 167
Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I Study
2010 · Jason A. Konner, Katherine M. Bell-McGuinn, et al. · Clinical Cancer Research · 160
89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
2014 · Neeta Pandit-Taskar, Joseph A. O’Donoghue, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 156
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2 -Amplified Esophagogastric Cancer
2018 · Francisco Sanchez-Vega, Jaclyn F. Hechtman, et al. · Cancer Discovery · 150
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
2016 · Neeta Pandit-Taskar, Joseph A. O’Donoghue, et al. · Journal of Nuclear Medicine · 146
PDF
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma
2012 · Patrick A. Ott, Richard D. Carvajal, et al. · Investigational New Drugs · 146
Biodistribution and Dosimetry of 18 F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies
2017 · Neeta Pandit-Taskar, Pat Zanzonico, et al. · Journal of Nuclear Medicine · 136
PDF
Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer
2008 · Andrea B. Apolo, Neeta Pandit-Taskar, et al. · Journal of Nuclear Medicine · 129
PDF
Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer
2017 · Joseph A. O'Donoghue, Jason S. Lewis, et al. · Journal of Nuclear Medicine · 126
PDF
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of 89Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody
2021 · Michael D. Farwell, Raymond F. Gamache, et al. · Journal of Nuclear Medicine · 125
PDF
SNMMI Procedure Standard/EANM Practice Guideline on Pediatric18F-FDG PET/CT for Oncology 1.0
2020 · Reza Vali, Adam Alessio, et al. · Journal of Nuclear Medicine · 125
PDF
Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients.
2006 · Neeta Pandit-Taskar, Lawrence T Dauer, et al. · PubMed · 123
Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer
2005 · Michael J. Morris, Chaitanya R. Divgi, et al. · Clinical Cancer Research · 116
PDF
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0
2022 · E. Lopci, R. J. Hicks, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 113
PDF
Works count: 517
Citation count: 10,410
H-index: 57
I10-index: 155
Year
Topic
Type